AML with TP53 mutations have been recently recognized as a different diagnostic entity [17], and its very adverse prognosis, incorporated in EL2017 risk recommendations, has been observed throughout all clinical series [29,30,31,32,33]. This evidence concerns the gene TP53 and acute myeloid leukemia.